Navigation Links
NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease

KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease (IBD).  Animal studies suggest that NX002 may have applications in acute and chronic diseases of the gastrointestinal tract, including Crohn’s disease and ulcerative colitis.  It has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury.  NX002 is currently in preclinical studies for the treatment of IBD and in late preclinical development as a potential treatment for oral mucositis.

“Issuance of this new patent is important given the promising utility of NX002 as a potential treatment for serious disorders of the gastrointestinal system,” said James Koziarz, President and CEO of NephRx.  “We have been encouraged by the efficacy demonstrated by NX002 in models of oral mucositis, and early studies suggest its distinctive mechanism of action also has potential as a novel treatment for inflammatory bowel disease.  This family of painful and disabling conditions affects more than a million patients in the U.S. alone, and despite recent advances, many remain poorly treated.”

NX002 is a peptide derived from the naturally occurring growth factor AMP-18.  Its multiple biological properties include the ability to protect cells from injury, stimulate cell growth and migration, and increase the accumulation of proteins that bind cells together.

The U.S. Patent and Trademark Office issued Patent No. 7910543, “Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors.”  Rights to this patent, which protects NX002 and related compounds, have been exclusively licensed to NephRx by the University of Chicago.

About Inflammatory Bowel DiseaseInflammatory bowel disease (IBD) refers to a group of inflammatory conditions of the colon and small intestine, including ulcerative colitis and Crohn's disease, which cause chronic inflammation of the intestinal tract and lead to a variety of symptoms, including ulceration, pain, vomiting, diarrhea, edema, bleeding and fluid loss.  IBD is a chronic condition with periods of active disease alternating with periods of remission.  It can limit quality of life and may lead to life-threatening complications. IBD is thought to result from an immune reaction of the body against its own intestinal tissue.  It is treated with surgery and with a variety of systemic and local anti-inflammatory and immunomodulatory agents, but many involve potentially serious side effects and efficacy varies.  According to the American College of Gastroenterology, there are more than one million people with IBD in the U.S. alone.  These diseases account for 700,000 physician visits per year and 100,000 annual hospitalizations.

About NephRxNephRx Corporation is a clinical-stage biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders, and diseases of the gastrointestinal tract, including mucositis, Crohn’s disease and ulcerative colitis.  NX001 is currently in Phase I testing and will be developed initially for the treatment of delayed graft function in kidney transplant patients.  NX002 is in late stage preclinical development as a potential treatment for oral mucositis and in preclinical studies for the treatment of inflammatory bowel disease.  For more information, visit Corp.

GendeLLindheim BioCom PartnersPhilip A. Long

Barbara Lindheim(269) 838-4785

(212) 918-4650

SOURCE NephRx Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002
2. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
7. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
8. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was ... inventor from Hillside, N.J. "Many people catch diseases simply from sitting on such ... always be protected from germs." , He developed the patent-pending QUDRATECS to eliminate ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... 27, 2015 , ... The moment you stop improving is ... fulfilling the needs of advisers and clients but going above and beyond to ... customer service. However, there's always room for improvement, which is why the entire ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
Breaking Medicine News(10 mins):